The combination therapy of TIM3 and PD-1/PD-L1 monoclonal antibodies, cobolimab and dostarlimab, respectively, have shown promising results in phase I trials of NSCLC patients resistant to anti-PD-1/PD-L1 therapy alone, displaying increased clinical activity in addition to manageable toxicity (Wolf et al., 2020). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.